Table 4.

Overview of weight change assessment in mice that received ²²⁴Ra-CaCO₃-MPs as a single treatment and in combination with both carboplatin-paclitaxel and carboplatin-PLD chemotherapy regimens.

224 Ra-CaCO 3 -MP-2 (5 mg, 22 kBq) vs. vehicle control
		Estimate	SE	95% CI	p-value
Intercept		−0.7547	0.3625	[−1.465; −0.044]	0.041
Time		2.9845	0.3951	[2.210; 3.759]	< 0.001
Time*treatment		0.9329	0.5319	[−0.110; 1.975]	0.097
224 Ra-CaCO 3 -MP-2 (5 mg, 27/34/39 kBq) vs. vehicle control
Intercept		−0.0792	0.2810	[−0.632; 0.473]	0.779
Time		2.5870	0.2699	[2.086; 3.102]	< 0.001
Time*treatment	27 kBq	−0.1453	0.3904	[−0.890; 0.577]	0.712
	34 kBq	−0.7783	0.3800	[−1.501; −0.073]	0.047
	39 kBq	−1.5413	0.3800	[−2.262; −0.835]	< 0.001
224 Ra-CaCO 3 -MP-2 (5 mg, 22 kBq) with carboplatin (80 mg/kg)-PLD (1.6 mg/kg) vs. carboplatin-PLD
Intercept		−0.1514	0.7267	[−1.576; 1.273]	0.836
Time		1.2681	0.4324	[0.421; 2.116]	0.006
Time*treatment		0.8688	0.5065	[−0.124; 1.862]	0.103
224 Ra-CaCO 3 -MP-2 (5 mg, 27/34/39 kBq) with carboplatin (60 mg/kg)-paclitaxel (10 mg/kg) vs. carboplatin-paclitaxel
Intercept		0.1806	0.2556	[−0.322; 0.683]	0.481
Time		1.5512	0.3093	[0.974; 2.133]	< 0.001
Time*treatment	27 kBq	−0.3239	0.4323	[−1.133; 0.484]	0.458
	34 kBq	−0.2156	0.4323	[−1.027; 0.590]	0.621
	39 kBq	0.0202	0.4323	[−0.792; 0.825]	0.963
224 Ra-CaCO 3 -MP-2 (5 mg, 22 kBq) vs. carboplatin (80 mg/kg)-PLD (1.6 mg/kg)
Intercept		−0.3848	0.4784	[−1.322; 0.553]	0.424
Time		2.2147	0.3974	[1.436; 2.994]	< 0.001
Time*treatment		0.6465	0.5148	[−0.363; 1.656]	0.225
224 Ra-CaCO 3 -MP-2 (5 mg, 27/34/39 kBq) vs. carboplatin (60 mg/kg)-paclitaxel (10 mg/kg)
Intercept		−0.1183	0.2762	[−0.665; 0.428]	0.670
Time		1.5848	0.2781	[1.049; 2.129]	< 0.001
Time*treatment	27 kBq	0.8301	0.3994	[0.046; 1.606]	0.045
	34 kBq	0.2130	0.3887	[−0.543; 0.963]	0.587
	39 kBq	−0.5364	0.3887	[−1.287; 0.210]	0.176

Statistical analysis was performed by fitting a linear mixed model.

PLD, pegylated liposomal doxorubicin; SE, standard error; CI, confidence interval.